Travere Therapeutics (NASDAQ:TVTX) Posts Quarterly Earnings Results, Misses Expectations By $0.78 EPS

Travere Therapeutics (NASDAQ:TVTX) issued its earnings results on Monday. The company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78), Briefing.com reports. The company had revenue of $41.40 million for the quarter, compared to analysts’ expectations of $43.46 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. The firm’s revenue for the quarter was up 34.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.27) earnings per share.

Travere Therapeutics Stock Down 0.6 %

Shares of Travere Therapeutics stock traded down $0.04 during trading hours on Thursday, hitting $6.78. The company had a trading volume of 49,157 shares, compared to its average volume of 1,268,325. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.47 and a quick ratio of 3.41. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $19.54. The company’s 50-day moving average is $6.99 and its two-hundred day moving average is $7.60. The company has a market cap of $516.03 million, a P/E ratio of -4.24 and a beta of 0.69.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on TVTX shares. Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of Travere Therapeutics in a research report on Tuesday. Wells Fargo & Company upped their price objective on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Friday, February 16th. Canaccord Genuity Group raised their target price on shares of Travere Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $13.00 price target on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.69.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.